Integration of azithromycin mass administration to 1-11-month-old children into an existing health platform to reduce child mortality: a cluster-randomised trial in Burkina Faso
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Azithromycin mass drug administration (MDA) in infants aged 1-11 months did not significantly reduce mortality in Burkina Faso. While scalable, this intervention showed no impact on infant mortality, suggesting broader age targeting may be more effective.
Area Of Science
- Global Health
- Infectious Diseases
- Pediatrics
Background
- Azithromycin mass drug administration (MDA) is known to reduce childhood mortality in children aged 1-59 months.
- Further evidence is required to determine the efficacy of targeting a narrower age range, specifically 1-11 months.
- This study integrated vitamin A delivery within the Child Health Days platform in Burkina Faso.
Purpose Of The Study
- To assess the efficacy of azithromycin MDA in reducing mortality among children aged 1-11 months in Burkina Faso.
- To evaluate the feasibility of integrating azithromycin MDA with vitamin A delivery into existing child health programs.
- To provide real-world evidence for policy decisions regarding azithromycin MDA for child survival.
Main Methods
- A double-masked, cluster-randomised, placebo-controlled trial was conducted in Burkina Faso.
- Primary healthcare catchment areas (CSPS) were randomized 2:1 to administer biannual azithromycin or placebo to children aged 1-11 months.
- Mortality rates were calculated using birth history data collected at the study endpoint.
Main Results
- Over 300,000 children participated, with 85% treatment coverage.
- Mortality rates were similar between the azithromycin and placebo groups (2.6 vs. 2.5 deaths per 1000 person-years).
- No significant difference in mortality rates was observed between the arms (IRR: 1.04; p=0.80), with no serious adverse events recorded.
Conclusions
- Azithromycin MDA for child survival is scalable and can be integrated into existing child health programs.
- The trial did not demonstrate a significant effect of azithromycin distribution on infant mortality in the 1-11 month age group.
- Future policy considerations should explore the benefits of azithromycin MDA for the broader age group of children up to 5 years old.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
At the different levels of the healthcare system, we see varying methods of healthcare used. These methods include managed care systems, case management, and primary healthcare.
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...